罗格列酮对动脉粥样硬化兔白介素-18、单核细胞趋化蛋白-1及基质金属蛋白酶-9表达的影响  

The Effect of Rosiglitazone on Expressions of IL-18,MCP-1 and MMP-9 in Rabbits with Atherosclerosis

作　　者：郭文芬[1] 李万玲[1] 贾军正[1] 王志禄[2] 徐芳[1] 蒙颖[1] 

机构地区：[1]兰州大学第一临床学院,兰州73000 [2]兰州大学第一医院心内科,兰州730000

出　　处：《中国药学杂志》2012年第20期1621-1625,共5页Chinese Pharmaceutical Journal

基　　金：甘肃省自然科学研究基金资助(1010RJZA122)

摘　　要：目的通过比较罗格列酮和辛伐他汀对动脉粥样硬化兔炎症因子的影响,探讨其抗动脉粥样硬化的作用机制。方法 36只雄性新西兰大白兔随机分为对照组、模型组、辛伐他汀组、罗格列酮组,采用皮下注射同型半胱氨酸硫内酯及高脂饮食相结合的方法建立动脉粥样硬化模型,酶联免疫吸附法检测血清白介素-18水平,免疫组化技术测定主动脉粥样斑块中单核细胞趋化蛋白-1和基质金属蛋白酶-9的表达。结果与对照组比较,其他3组血清白介素-18水平、主动脉粥样斑块中单核细胞趋化蛋白-1和基质金属蛋白酶-9表达显著增高(P<0.05);罗格列酮组和辛伐他汀组白介素-18水平、单核细胞趋化蛋白-1和基质金属蛋白酶-9表达较模型组明显降低(P<0.05)。罗格列酮组白介素-18较辛伐他汀组降低明显(P<0.05),单核细胞趋化蛋白-1和基质金属蛋白酶-9的表达在两组间无统计学差异(P>0.05)。结论罗格列酮可降低动脉粥样硬化兔血清IL-18和主动脉粥样斑块中单核细胞趋化蛋白-1和基质金属蛋白酶-9的表达,抑制动脉粥样硬化的进展,其机制与抗炎作用有关。OBJECTIVE To compare the effects of rosiglitazone and simvastatin on inflammatory factors in atherosclerotic rabbits and to explore the anti-athcrosclerosis mechanism. METHODS Thirty-six male New Zealand rabbits were randomly divided into four groups： control group, model group, simvastatin group, and rosiglitazone group. Subcutaneous injection of dl-homoeyesteine thiolactone combined with high fat diet was used to reproduce atherosclerotie rabbit model, the serum level of interleukin-18（IL-18） was examined by ELISA, and the expressions of monocyte ehemoattractant-1 （ MCP-1 ） and matrix metalloproteinase-9 （MMP-9） in aortic atheroselerotic plaque were examined by immunohistochemistry. RESULTS Compared with the control group, the serum levels of IL-18 and the expressions of MMP-9 and MCP-1 in aortic atherosclerotic plaque were increased obviously in the other three groups （P 〈 0. 05 ） ; compared with model group, the serum levels of IL-18 and the expressions of MMP-9 and MCP-1 in rosiglitazone and simvastatin group were decreased significantly （P 〈 0. 01 ）, the level of IL-18 in rosiglitazone group decreased significantly （P 〈 0. 05 ）, but the expressions of MMP-9 and MCP-1 in rosiglitazone group and simvastatin group had no statistic difference（P 〉0. 05 ）. CONCLU- SION Rosiglitazone can decrease the serum level of IL-18 and the expressions of MCP-1 and MMP-9 in aortic atheroselerotic plaque, and inhibit the development of atherosclerosis. The mechanism is related to anti-inflammation.

关 键 词：罗格列酮 动脉粥样硬化 白介素-18 单核细胞趋化蛋白-1 基质金属蛋白酶-9 

分 类 号：R543.1[医药卫生—心血管疾病]